Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium‐glucose co‐transporter‐2 inhibitor: The Impact GLP‐1 CKD study

A significantly greater reduction in HbA1c of -1.3% was observed in adults with type 2 diabetes and chronic kidney disease treated with a glucagon-like peptide-1 receptor agonist compared to those treated with basal insulin.

• Weight loss was greater in the glucagon-like peptide-1 receptor agonist group, averaging -3.4 kg, compared to -2.6 kg in the basal insulin group.
• The decline in kidney function, measured by estimated glomerular filtration rate, was less pronounced in the glucagon-like peptide-1 receptor agonist group, at -0.3 mL/min/1.73m compared to -2.4 mL/min/1.73m in the basal insulin group.
• No significant difference was found in the change in albuminuria between the two treatment groups.
• Self-reported hypoglycaemic events and therapy discontinuations did not differ between the glucagon-like peptide-1 receptor agonist and basal insulin cohorts.

AI simplified